Bader et al., 2016 - Google Patents
Correlating HIV tropism with immunological response under combination antiretroviral therapyBader et al., 2016
View PDF- Document ID
- 17649651229369026385
- Author
- Bader J
- Schöni‐Affolter F
- Böni J
- Gorgievski‐Hrisoho M
- Martinetti G
- Battegay M
- Klimkait T
- Swiss HIV Cohort Study
- Aubert V
- Bernasconi E
- Bucher H
- Burton‐Jeangros C
- Calmy A
- Cavassini M
- Dollenmaier G
- Egger M
- Elzi L
- Fehr J
- Fellay J
- Furrer H
- Fux C
- Günthard H
- Haerry D
- Hasse B
- Hirsch H
- Hoffmann M
- Hösli I
- Kahlert C
- Kaiser L
- Keiser O
- Kouyos R
- Kovari H
- Ledergerber B
- de Tejada B
- Metzner K
- Müller N
- Nadal D
- Nicca D
- Pantaleo G
- Rauch A
- Regenass S
- Rickenbach M
- Rudin C
- Schmid P
- Schüpbach J
- Speck R
- Tarr P
- Telenti A
- Trkola A
- Vernazza P
- Weber R
- Yerly S
- Publication year
- Publication venue
- HIV medicine
External Links
Snippet
Objectives A significant percentage of patients infected with HIV‐1 experience only suboptimal CD 4 cell recovery while treated with combination therapy (cART). It is still unclear whether viral properties such as cell tropism play a major role in this incomplete …
- 238000002560 therapeutic procedure 0 title description 25
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriphage
- C12Q1/701—Specific hybridization probes
- C12Q1/702—Specific hybridization probes for retroviruses
- C12Q1/703—Viruses associated with AIDS
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
- G01N33/56988—AIDS or HTLV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
- G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
- G01N2333/16—HIV-1, HIV-2
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Westby et al. | Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir | |
| Avettand-Fènoël et al. | Total HIV-1 DNA, a marker of viral reservoir dynamics with clinical implications | |
| Klatt et al. | Limited HIV infection of central memory and stem cell memory CD4+ T cells is associated with lack of progression in viremic individuals | |
| Gonzalo-Gil et al. | Mechanisms of virologic control and clinical characteristics of HIV+ elite/viremic controllers | |
| Raymond et al. | Correlation between genotypic predictions based on V3 sequences and phenotypic determination of HIV-1 tropism | |
| Schnell et al. | Compartmentalization and clonal amplification of HIV-1 variants in the cerebrospinal fluid during primary infection | |
| Del Prete et al. | TLR7 agonist administration to SIV-infected macaques receiving early initiated cART does not induce plasma viremia | |
| Lerner et al. | The gut mucosal viral reservoir in HIV-infected patients is not the major source of rebound plasma viremia following interruption of highly active antiretroviral therapy | |
| Delobel et al. | Population-based sequencing of the V3 region of env for predicting the coreceptor usage of human immunodeficiency virus type 1 quasispecies | |
| Omondi et al. | HIV subtype and Nef-mediated immune evasion function correlate with viral reservoir size in early-treated individuals | |
| Abbate et al. | Detection of quasispecies variants predicted to use CXCR4 by ultra-deep pyrosequencing during early HIV infection | |
| Del Prete et al. | Effect of suberoylanilide hydroxamic acid (SAHA) administration on the residual virus pool in a model of combination antiretroviral therapy-mediated suppression in SIVmac239-infected indian rhesus macaques | |
| Henrich et al. | Viremic control and viral coreceptor usage in two HIV-1-infected persons homozygous for CCR5 Δ32 | |
| Swenson et al. | Genotypic analysis of the V3 region of HIV from virologic nonresponders to maraviroc-containing regimens reveals distinct patterns of failure | |
| Bosman et al. | Development of sensitive dd PCR assays to reliably quantify the proviral DNA reservoir in all common circulating HIV subtypes and recombinant forms | |
| Bader et al. | Correlating HIV tropism with immunological response under combination antiretroviral therapy | |
| Raymond et al. | Genotypic prediction of human immunodeficiency virus type 1 CRF02-AG tropism | |
| Lewin et al. | Virologic determinants of success after structured treatment interruptions of antiretrovirals in acute HIV-1 infection | |
| Weber et al. | Sensitive cell-based assay for determination of human immunodeficiency virus type 1 coreceptor tropism | |
| Omondi et al. | HIV proviral burden, genetic diversity, and dynamics in viremic controllers who subsequently initiated suppressive antiretroviral therapy | |
| Bader et al. | Therapeutic immune recovery and reduction of CXCR4-tropic HIV-1 | |
| Kalu et al. | Monophylogenetic HIV-1C epidemic in Ethiopia is dominated by CCR5-tropic viruses–an analysis of a prospective country-wide cohort | |
| Soriano et al. | When and how to use maraviroc in HIV-infected patients | |
| Frange et al. | Low frequency of CXCR4-using viruses in patients at the time of primary non-subtype-B HIV-1 infection | |
| Mir et al. | Simian immunodeficiency virus-induced alterations in monocyte production of tumor necrosis factor alpha contribute to reduced immune activation in sooty mangabeys |